Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs Xencor, Inc.

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Axsome Therapeutics, Inc. and Xencor, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.

Axsome Therapeutics, Inc.

From 2014 to 2023, Axsome Therapeutics increased its R&D expenses by over 2,000%, peaking in 2023 with a remarkable 98% growth compared to the previous year. This surge underscores Axsome's aggressive pursuit of novel therapies.

Xencor, Inc.

Xencor, Inc. has consistently outpaced Axsome in R&D spending, with a steady upward trend. By 2023, Xencor's R&D expenses had grown by approximately 1,270% since 2014, highlighting its sustained commitment to innovation.

Both companies exemplify the biotech sector's relentless drive to push the boundaries of medical research, promising exciting advancements in the years to come.